Veeva Systems (VEEV)
(Delayed Data from NYSE)
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.67 USD
+0.14 (0.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $204.53 -0.14 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.
Varian Medical's (VAR) Halcyon Gets NMPA Approval in China
by Zacks Equity Research
Varian Medical (VAR) enjoys significant international presence in radiotherapy.
Walgreens Gains from New Alliances, International Expansion
by Zacks Equity Research
Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.
Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) impressive Q3 results can be attributed to the Subscription Service segment's solid performance. An upbeat FY19 guidance instills investor optimism in the stock
Veeva Systems (VEEV) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 18.42% and 3.93%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?
Integra's (IART) Margin Pressure Hurts, Global Prospects High
by Zacks Equity Research
Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).
PRA Health Launches PSN to Expand in Pediatric Care, Stock Up
by Zacks Equity Research
PRA Health's (PRAH) Center for Pediatric Clinical Development is likely to enhance pediatric clinical testing and design with the latest move.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
Cardinal Health to Highlight Cost-Control Approach in ASHP
by Zacks Equity Research
Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.
Quest Diagnostics to Buy Laboratory Services Unit in Midwest
by Zacks Equity Research
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
CVS Health (CVS) Gets Final Approval to Close Aetna Deal
by Zacks Equity Research
Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.
Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail
by Zacks Equity Research
The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.
Align Technology's New iTero Scanner Updates to Boost Uptake
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
Here's Why Investors Should Hold Medidata (MDSO) Stock Now
by Zacks Equity Research
Solid prospects in the Rave Genomics platform are likely to provide Medidata (MDSO) a competitive edge in the MedTech space.
Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull
by Zacks Equity Research
Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.
PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects
by Zacks Equity Research
PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.
Here's Why You Should Invest in Merit Medical (MMSI) Now
by Zacks Equity Research
A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.
Here's Why You Should Invest in Abiomed (ABMD) Right Now
by Zacks Equity Research
Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.
Medtronic's Deal With Nutrino Health to Boost Diabetes Arm
by Zacks Equity Research
Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.
Medtronic Gets Health Canada License for Visualase System
by Zacks Equity Research
Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Can Segmental Growth Boost Veeva Systems' (VEEV) Q3 Earnings?
by Zacks Equity Research
Veeva Systems (VEEV) likely to gain from solid segmental show in fiscal Q3; competition stiff.
Veeva Systems (VEEV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Veeva (VEEV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.